| Literature DB >> 31653568 |
Elsa Callen1, Dali Zong1, Wei Wu1, Nancy Wong1, Andre Stanlie1, Momoko Ishikawa1, Raphael Pavani1, Lavinia C Dumitrache2, Andrea K Byrum3, Carlos Mendez-Dorantes4, Paula Martinez5, Andres Canela1, Yaakov Maman1, Amanda Day1, Michael J Kruhlak6, Maria A Blasco5, Jeremy M Stark4, Nima Mosammaparast3, Peter J McKinnon2, André Nussenzweig7.
Abstract
53BP1 activity drives genome instability and lethality in BRCA1-deficient mice by inhibiting homologous recombination (HR). The anti-recombinogenic functions of 53BP1 require phosphorylation-dependent interactions with PTIP and RIF1/shieldin effector complexes. While RIF1/shieldin blocks 5'-3' nucleolytic processing of DNA ends, it remains unclear how PTIP antagonizes HR. Here, we show that mutation of the PTIP interaction site in 53BP1 (S25A) allows sufficient DNA2-dependent end resection to rescue the lethality of BRCA1Δ11 mice, despite increasing RIF1 "end-blocking" at DNA damage sites. However, double-mutant cells fail to complete HR, as excessive shieldin activity also inhibits RNF168-mediated loading of PALB2/RAD51. As a result, BRCA1Δ1153BP1S25A mice exhibit hallmark features of HR insufficiency, including premature aging and hypersensitivity to PARPi. Disruption of shieldin or forced targeting of PALB2 to ssDNA in BRCA1D1153BP1S25A cells restores RNF168 recruitment, RAD51 nucleofilament formation, and PARPi resistance. Our study therefore reveals a critical function of shieldin post-resection that limits the loading of RAD51.Entities:
Keywords: 53BP1; BRCA1; PARPi; aging; cancer; homologous recombination; resection; shieldin
Mesh:
Substances:
Year: 2019 PMID: 31653568 PMCID: PMC6993210 DOI: 10.1016/j.molcel.2019.09.024
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970